Novo Nordisk A/S Stock Is Estimated To Be Fairly Valued

Author's Avatar
Mar 29, 2021
Article's Main Image

The stock of Novo Nordisk A/S (NYSE:NVO, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $67.78 per share and the market cap of $156.4 billion, Novo Nordisk A/S stock is believed to be fairly valued. GF Value for Novo Nordisk A/S is shown in the chart below.

US08TU.png?1616987522

Because Novo Nordisk A/S is fairly valued, the long-term return of its stock is likely to be close to the rate of its business growth, which averaged 6.4% over the past three years and is estimated to grow 6.31% annually over the next three to five years.

Link: These companies may deliever higher future returns at reduced risk.

Companies with poor financial strength offer investors a high risk of permanent capital loss. To avoid permanent capital loss, an investor must do their research and review a company's financial strength before deciding to purchase shares. Both the cash-to-debt ratio and interest coverage of a company are a great way to to understand its financial strength. Novo Nordisk A/S has a cash-to-debt ratio of 1.23, which which ranks worse than 80% of the companies in Biotechnology industry. The overall financial strength of Novo Nordisk A/S is 7 out of 10, which indicates that the financial strength of Novo Nordisk A/S is fair. This is the debt and cash of Novo Nordisk A/S over the past years:

1616987522885.png

It is less risky to invest in profitable companies, especially those with consistent profitability over long term. A company with high profit margins is usually a safer investment than those with low profit margins. Novo Nordisk A/S has been profitable 10 over the past 10 years. Over the past twelve months, the company had a revenue of $19.7 billion and earnings of $2.786 a share. Its operating margin is 42.64%, which ranks better than 96% of the companies in Biotechnology industry. Overall, the profitability of Novo Nordisk A/S is ranked 8 out of 10, which indicates strong profitability. This is the revenue and net income of Novo Nordisk A/S over the past years:

1616987523269.png

Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term performance of a company's stock. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of Novo Nordisk A/S is 6.4%, which ranks in the middle range of the companies in Biotechnology industry. The 3-year average EBITDA growth rate is 6.5%, which ranks in the middle range of the companies in Biotechnology industry.

Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, Novo Nordisk A/S's return on invested capital is 35.07, and its cost of capital is 4.42. The historical ROIC vs WACC comparison of Novo Nordisk A/S is shown below:

1616987523666.png

To conclude, the stock of Novo Nordisk A/S (NYSE:NVO, 30-year Financials) gives every indication of being fairly valued. The company's financial condition is fair and its profitability is strong. Its growth ranks in the middle range of the companies in Biotechnology industry. To learn more about Novo Nordisk A/S stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.